# Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC

> **NCT07172386** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University Second Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Renal Cell Carcinoma (RCC)

## Interventions

- **DRUG:** Toripalimab and axitinib

## Key facts

- **NCT ID:** NCT07172386
- **Lead sponsor:** Tianjin Medical University Second Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07172386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07172386, "Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07172386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*